Ambit Pharmaceuticals
Ambit Pharmaceuticals is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Ambit Pharmaceuticals.
Ambit Pharmaceuticals is a company.
Key people at Ambit Pharmaceuticals.
Key people at Ambit Pharmaceuticals.
Ambit Biosciences (often referred to as Ambit Pharmaceuticals in some contexts) was a biopharmaceutical company based in San Diego, California, focused on discovering and developing small molecule kinase inhibitors to treat cancers like acute myeloid leukemia (AML), inflammatory diseases, and other conditions.[1][2][3] Its lead product, quizartinib (AC220), targeted relapsed or refractory AML through a partnership with Astellas Pharma, while its pipeline included other candidates like AC480 (pan-HER inhibitor) and AC430 (JAK2 inhibitor).[1][2][3] The company went public on NASDAQ (AMBI) in 2013 after raising significant venture funding, but was acquired by Daiichi Sankyo in 2014, ceasing independent operations.[1][2]
Ambit served oncology patients and pharmaceutical partners, addressing unmet needs in aggressive cancers by targeting specific kinases involved in cell division and disease progression.[3] It demonstrated growth through Series D funding ($30M in 2010 from investors like Foresite Capital), an IPO, and acquisition driven by quizartinib's promise, though post-acquisition development continued under Daiichi Sankyo.[1][2]
Founded in the mid-2000s (exact year not specified in records), Ambit Biosciences emerged from proprietary research into kinase inhibitors, building a pipeline of internally developed therapeutics.[1] Key early milestones included collaborations like the worldwide agreement with Astellas for quizartinib and licensing deals, such as CEP-32496 (BRAF inhibitor) to Cephalon.[2] The company gained traction via venture funding, notably a $30M Series D-2 round in June 2010 led by Apposite Capital with participants including Perseus-Soros, OrbiMed, and Foresite Capital, followed by additional investment from Foresite in 2013.[1][2]
Pivotal moments were its 2013 IPO on NASDAQ under "AMBI" and the 2014 acquisition by Daiichi Sankyo for its quizartinib asset, marking the end of independent operations as a defunct entity.[1][2]
(Note: A separate entity, Ambit Inc., exists as an analytics firm for rare/specialty biopharma patient identification, but search results confirm the pharmaceutical context aligns with Ambit Biosciences.[4][5])
Ambit rode the early 2010s wave of precision oncology, targeting kinase-driven cancers amid rising demand for targeted therapies over broad chemotherapies.[1][2][3] Timing was ideal post-genomic era, with kinase inhibitors like FLT3 blockers addressing AML's poor prognosis (5-year survival ~30%), filling gaps in relapsed cases.[3] Market forces favoring biotech IPOs and Big Pharma acquisitions (e.g., Daiichi Sankyo's move) propelled Ambit, influencing the ecosystem by validating investor interest in oncology pipelines—Foresite Capital's involvement highlighted VC trends in high-unmet-need areas.[1][2]
Its acquisition accelerated quizartinib's development, contributing to broader advancements in hematologic malignancies and inspiring similar inhibitor-focused biotechs.
Ambit Biosciences' legacy endures through quizartinib, now advanced by Daiichi Sankyo (with FDA approvals in later years for FLT3-mutated AML), underscoring the value of focused kinase platforms.[1] Post-acquisition, its influence lives in integrated pipelines at larger pharmas. Looking ahead, trends like AI-driven drug discovery and next-gen kinase modulators could revive similar models, but Ambit's story warns of acquisition risks in biotech. As a pioneer in selective inhibitors, it set a blueprint for targeting rare mutations, tying back to its core mission of tackling aggressive diseases where few options existed.
